Allchemy

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

Sensae is an AI-powered biofeedback platform that uses data-driven techniques to enhance personal well-being. It integrates physiology and psychology using haptic biofeedback to help people reconnect with their inner emotions. Sensae's technology provides deep insights into the body and mind, uncovering hidden emotional patterns and revealing the complex web of human behavior and thinking. The platform offers a range of modules, including advanced bio-monitoring, stress assessment, heart rate variability assessment, and psychometric testing. Sensae's proprietary wearable device provides haptic biofeedback, creating a direct feedback loop that ensures the effectiveness of both stimuli and interventions.

Exscientia is a technology-driven drug design and development company that combines precision design with integrated experimentation to create more effective medicines for patients faster. They operate at the interfaces of human ingenuity, artificial intelligence (AI), automation, and physical engineering, pioneering the use of AI in drug discovery. Exscientia aims to change the underlying economics of drug discovery by rapidly advancing the best scientific ideas into medicines for patients.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus' innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, which identifies and closes gaps in care; LENS, which finds, accesses, and analyzes multimodal real-world data; and ALGOS, algorithmic models connected to Tempus' assays to provide additional insight.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover valuable insights. The platform is purpose-built for various conditions such as cancer, immune, endocrine, metabolic system, chronic diseases, aging, infectious diseases, and mental health, offering solutions for early biomarker discovery, drug repurposing, lead identification, compound optimization, trial monitoring, and response to treatment. JADBio is trusted by partners in precision health & medicine and is continuously evolving to disrupt drug discovery times and costs at all stages.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Intelligencia AI is a leading provider of AI-powered solutions for the pharmaceutical industry. Our suite of solutions helps de-risk and enhance clinical development and decision-making. We use a combination of data, AI, and machine learning to provide insights into the probability of success for drugs across multiple therapeutic areas. Our solutions are used by many of the top global pharmaceutical companies to improve their R&D productivity and make more informed decisions.

Altera is an applied research lab focused on building digital human beings with fundamental human qualities. Led by Dr. Robert Yang, the team consists of computational neuroscientists, physics olympiads, and engineers from prestigious institutions. Their mission is to create digital beings that enhance human-to-human interactions, offering empathy, fun, friendship, and productivity at an unprecedented scale. Leveraging a state-of-the-art Composite Architecture inspired by the brain, Altera aims to develop agents with empathy, memory, and social norms. Starting with products in games, Altera plans to expand into multi-agent simulations and physical embodiment of digital intelligence, aspiring to become the most consequential technology company in the world.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

TensorFlow is an end-to-end platform for machine learning. It provides a wide range of tools and resources to help developers build, train, and deploy ML models. TensorFlow is used by researchers and developers all over the world to solve real-world problems in a variety of domains, including computer vision, natural language processing, and robotics.

Tempus is an AI-enabled precision medicine company that brings the power of data and artificial intelligence to healthcare. With the power of AI, Tempus accelerates the discovery of novel targets, predicts the effectiveness of treatments, identifies potentially life-saving clinical trials, and diagnoses multiple diseases earlier. Tempus's innovative technology includes ONE, an AI-enabled clinical assistant; NEXT, a tool to identify and close gaps in care; LENS, a platform to find, access, and analyze multimodal real-world data; and ALGOS, algorithmic models connected to Tempus's assays to provide additional insight.

Ogma is an interpretable symbolic general problem-solving model that utilizes a symbolic sequence modeling paradigm to address tasks requiring reliability, complex decomposition, and without hallucinations. It offers solutions in areas such as math problem-solving, natural language understanding, and resolution of uncertainty. The technology is designed to provide a structured approach to problem-solving by breaking down tasks into manageable components while ensuring interpretability and self-interpretability. Ogma aims to set benchmarks in problem-solving applications by offering a reliable and transparent methodology.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Deepcell is a company that develops technology for single-cell analysis. Their REM-I platform combines label-free imaging, deep learning, and gentle sorting to leverage single cell morphology as a high-dimensional quantitative readout. This allows researchers to gain insights into cells' phenotype and function to address important research questions across biology.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Wildlife Insights is an AI application that brings cutting-edge technology to wildlife conservation. It streamlines decision-making by providing machine learning models and tools to manage, analyze, and share camera trap data. Users can easily upload, identify, analyze, and discover wildlife through the platform, enabling better decisions to help wildlife thrive globally.

BioloGPT is an AI tool designed to answer biology-related questions with insights and graphs. It provides information on various topics such as maintaining a healthy gut microbiome, foods for a healthy immune system, effects of cannabis on the brain, risks of Covid-19 vaccines, and advancements in psoriasis treatment. The tool is updated daily and cites full papers to support its answers.

Bichos ID de Fucesa is an AI tool that allows users to explore and identify insects, arachnids, and other arthropods using artificial intelligence. Users can discover the most searched bugs, explore new discoveries made by the community, and view curated organisms. The platform aims to expand knowledge about the fascinating world of arthropods through AI-powered identification.

HoloEye.AI is a transformative AI biological intelligence company that leverages cutting-edge artificial intelligence technology to revolutionize the field of biological research. The platform offers advanced AI solutions for analyzing complex biological data, enabling researchers to gain deeper insights and accelerate scientific discoveries.

Lavo Life Sciences is an AI-accelerated crystal structure prediction application that aims to accelerate drug development processes. The platform provides solutions for de-risking pipelines, optimizing solid-state formulations, and avoiding late-stage surprises using AI technology. Lavo Life Sciences combines the expertise of chemists and engineers in AI and computational chemistry to offer innovative solutions for drug development teams.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

C&EN, a publication of the American Chemical Society, provides the latest news and insights on the chemical industry, including research, technology, business, and policy. It covers a wide range of topics, including analytical chemistry, biological chemistry, business, careers, education, energy, environment, food, materials, people, pharmaceuticals, physical chemistry, policy, research integrity, safety, and synthesis.

Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

XtalPi is a world-leading technology company driven by artificial intelligence (AI) and robotics to innovate in the fields of life sciences and new materials. Founded in 2015 at the Massachusetts Institute of Technology (MIT), the company is committed to realizing digital and intelligent innovation in the fields of life sciences and new materials. Based on cutting-edge technologies and capabilities such as quantum physics, artificial intelligence, cloud computing, and large-scale experimental robot clusters, the company provides innovative technologies, services, and products for global industries such as biomedicine, chemicals, new energy, and new materials.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

HUAWEI Cloud Pangu is an AI tool designed for accelerating drug discovery by optimizing drug molecules. It offers features such as Molecule Search, Molecule Optimizer, and Pocket Molecule Design. Users can submit molecules for optimization and view historical optimization results. The tool is based on the MindSpore framework and has been visited over 300,000 times since August 23, 2021.

PharmaTrace is an advanced healthcare ecosystem that utilizes blockchain technology and artificial intelligence to revolutionize the pharmaceutical industry. It offers solutions for track and trace, chronic disease forecasting, and digital transformation in the pharmaceutical supply chain. The platform aims to enhance business processes, improve patient care, and increase data security through innovative technologies. PharmaTrace provides customizable templates, scalable solutions, and easy access to blockchain-based technologies for pharmaceutical companies, pharmacies, insurances, and other stakeholders in the industry.

MediSearch is an AI-powered application that provides direct science-based answers to medical questions. Users can filter questions based on their complexity level and receive detailed information on various health topics. The application aims to assist individuals in understanding medical information and making informed decisions about their health. It is important to note that MediSearch is not a substitute for a medical professional and users should consult healthcare providers for personalized medical advice.

Medical Chat is an advanced AI assistant designed for healthcare professionals, providing instant and accurate medical answers for both human and veterinary medicine. Its capabilities include diagnosing medical conditions, generating differential diagnosis reports, creating patient-specific clinic plans, and offering comprehensive drug information. Medical Chat utilizes the latest LLM models, including ChatGPT 3.5 and 4.0, to deliver reliable and up-to-date medical knowledge. The platform also features a vast database of professional medical textbooks, veterinary books, and PubMed articles, ensuring evidence-based responses. With its HIPAA compliance and commitment to data privacy, Medical Chat empowers healthcare providers to enhance their diagnostic capabilities and improve patient outcomes.

SymptomChecker.io is an AI-powered medical symptom checker that allows users to describe their symptoms in their own words and receive non-reviewed AI-generated responses. It is important to note that this tool is not intended to offer medical advice, diagnosis, or treatment and should not be used as a substitute for professional medical advice. In the case of a medical emergency, please contact your physician or dial 911 immediately.

Clever Health is a virtual care provider that offers a variety of services, including urgent care, primary care, mental health support, and medication management. Clever Health uses artificial intelligence (AI) to power its services, which allows it to provide care that is more efficient, affordable, and convenient than traditional healthcare. Clever Health's services are available 24/7, and patients can access care from anywhere with an internet connection.